<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35344464</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.</ArticleTitle><Pagination><StartPage>2044255</StartPage><MedlinePgn>2044255</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2044255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2044255</ELocationID><Abstract><AbstractText>An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive one of 3 dose levels of sIPV or a conventional IPV based on Salk strains (cIPV). Poliovirus-neutralizing antibodies were measured before the first dose and 28 days after the third dose. Reactogenicity was assessed for 7 days and unsolicited adverse events (AEs) for 28 days after each vaccination. Serious AEs (SAEs) were recorded throughout the study. Solicited AEs were mostly mild to moderate. None of the SAEs reported in the study were judged vaccine related, including one fatal SAE due to aspiration of vomitus that occurred 26 days after the third dose of low-dose sIPV. After 3 sIPV vaccinations and across all dose levels, seroconversion (SC) rates were at least 92% against Sabin poliovirus types and at least 80% against Salk types, with a dose-response in neutralizing antibody geometric mean titers (GMTs) observed across the 3 sIPV groups. Compared to cIPV, the 3 sIPV groups displayed similar or higher SC rates and GMTs against the 3 Sabin types but showed a lower response against Salk types 1 and 2; this was most visible for Salk type 1. While the PER.C6® cell line-based sIPV showed an acceptable safety profile and immunogenicity in infants, lower seroprotection against type 1 warrants optimization of dose level and additional clinical evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ong-Lim</LastName><ForeName>Anna Lisa</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukarev</LastName><ForeName>Georgi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Vaccines AG, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinidad-Aseron</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>De La Salle University Medical Center, Cavite, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caparas-Yu</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>De La Salle Medical and Health Sciences Institute, Cavite, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greijer</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duchene</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheper</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Paassen</LastName><ForeName>Vitalija</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Gars</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Conor P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0001-7108-1168</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuitemaker</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8563-2266</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douoguih</LastName><ForeName>Macaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquet</LastName><ForeName>Jeanne-Marie</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-7081-7022</Identifier><AffiliationInfo><Affiliation>Janssen Vaccines &amp; Prevention B.V., Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Inactivated</Keyword><Keyword MajorTopicYN="N">PER.C6® cell line</Keyword><Keyword MajorTopicYN="N">Sabin</Keyword><Keyword MajorTopicYN="N">infants</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>G.Sh., A.G., M.Du., G.Sc., V.v.P., M.L.G., H.S. and M.Do. are full-time employees of the study sponsor. C.P.C. was a full-time employee of the sponsor at the time of the trial, J.-M. J. is an independent consultant under contract with the study sponsor. A.L.O.-L, M.T.-A., and D.C.-Y. have received grants from Janssen Vaccines to finance the conduct of this study in their institution. G.Sh, G.Sc, M.L.G., H.S., and A.G hold shares in Johnson &amp; Johnson.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>17</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35344464</ArticleId><ArticleId IdType="pmc">PMC9196784</ArticleId><ArticleId IdType="doi">10.1080/21645515.2022.2044255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative, World Health Organization. Polio endgame strategy 2019-2023. Eradication, integration, certification and containment. [accessed 2021 June
30]. http://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">27039410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard AN, Datta SD, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF, Zaffran M.. Progress toward polio eradication — worldwide, January 2018–March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–89. doi:10.15585/mmwr.mm6925a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6925a4</ArticleId><ArticleId IdType="pmc">PMC7316320</ArticleId><ArticleId IdType="pubmed">32584798</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative . GPEI polio today WPV reports. [accessed 2021 June
30]. https://polioeradication.org/polio-today/polio-now/this-week/.</Citation></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Quddus A, Sutter R, Vertefeuille JF, Wenger J, Wassilak SGF, et al. Update on vaccine-derived poliovirus outbreaks — worldwide, January 2018–June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024–28. doi:10.15585/mmwr.mm6845a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6845a4</ArticleId><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Strategic Advisory Group of Experts . Meeting of the strategic advisory group of experts on immunization, October 2020 – conclusions and recommendations. no. 48. Wkly Epidemiol Rep 2020;95:585–608.</Citation></Reference><Reference><Citation>Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB.. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(suppl_1):S459–64. doi:10.1093/infdis/jiu128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu128</ArticleId><ArticleId IdType="pubmed">25316868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975–85. doi:10.1016/j.vaccine.2014.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.11.015</ArticleId><ArticleId IdType="pubmed">25448090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Vaccine. 2020;38:6274–79. doi:10.1016/j.vaccine.2020.07.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.07.042</ArticleId><ArticleId IdType="pubmed">32747216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, et al. Per.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine. 2013;31(5):850–56. doi:10.1016/j.vaccine.2012.10.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.070</ArticleId><ArticleId IdType="pubmed">23123018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, et al. Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV. Vaccine. 2015;33(48):6611–16. doi:10.1016/j.vaccine.2015.10.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.091</ArticleId><ArticleId IdType="pubmed">26529068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018;36(46):6979–87. doi:10.1016/j.vaccine.2018.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.068</ArticleId><ArticleId IdType="pmc">PMC6219454</ArticleId><ArticleId IdType="pubmed">30314910</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9(13):1909–17. doi:10.1089/hum.1998.9.13-1909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.1998.9.13-1909</ArticleId><ArticleId IdType="pubmed">9741429</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021;21(4):493–506. doi:10.1016/S1473-3099(20)30476-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30476-X</ArticleId><ArticleId IdType="pubmed">33217361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, et al. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2021;39:3081–101. doi:10.1016/j.vaccine.2020.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7532807</ArticleId><ArticleId IdType="pubmed">33676782</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels I, Leroux-Roels G, Shukarev G, Schuitemaker H, Cahill C, de Rooij R, Struijs M, van Zeeburg H, Jacquet JM. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: A phase 1 randomized controlled trial in adults. Hum Vaccin Immunother. 2021;17(5):1366–73. doi:10.1080/21645515.2020.1812315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1812315</ArticleId><ArticleId IdType="pmc">PMC8078678</ArticleId><ArticleId IdType="pubmed">33175637</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–43. doi:10.1093/infdis/jir723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir723</ArticleId><ArticleId IdType="pubmed">22158682</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain–based inactivated poliovirus vaccine. J Infect Dis. 2016;214(11):1728–34. doi:10.1093/infdis/jiw433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw433</ArticleId><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis. 2013;208(2):275–83. doi:10.1093/infdis/jit155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit155</ArticleId><ArticleId IdType="pubmed">23568174</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 2014;32:4938–44. doi:10.1016/j.vaccine.2014.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.029</ArticleId><ArticleId IdType="pubmed">25043278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Sumino S, Takanami Y, Mitsuya N, Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother. 2018;14(12):2940–49. doi:10.1080/21645515.2018.1504538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1504538</ArticleId><ArticleId IdType="pmc">PMC6343622</ArticleId><ArticleId IdType="pubmed">30047808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018;36:6782–89. doi:10.1016/j.vaccine.2018.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.023</ArticleId><ArticleId IdType="pubmed">30249424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, et al. Immunogenicity and safety of a Sabin strain–based inactivated polio vaccine: A phase 3 clinical trial. J Infect Dis. 2019;220(10):1551–57. doi:10.1093/infdis/jiy736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy736</ArticleId><ArticleId IdType="pubmed">30958543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Li G, Zhang C, Zhi H, Zhu J, Wang J, Liang Q, Hu Y, Li C. A phase ΙΙ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine. Hum Vaccin Immunother. 2020;16(11):2641–48. doi:10.1080/21645515.2020.1745593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1745593</ArticleId><ArticleId IdType="pmc">PMC7733909</ArticleId><ArticleId IdType="pubmed">32347778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer JP, Jimeno J, Han HH, Lin S, Hartmann K, Borkowski A, Saez-Llorens X. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. Vaccine. 2020;38:5313–23. doi:10.1016/j.vaccine.2020.05.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.05.081</ArticleId><ArticleId IdType="pmc">PMC7347011</ArticleId><ArticleId IdType="pubmed">32563609</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, et al. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: A randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis. 2020. doi:10.1093/infdis/jiaa770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa770</ArticleId><ArticleId IdType="pmc">PMC9400411</ArticleId><ArticleId IdType="pubmed">33351072</ArticleId></ArticleIdList></Reference><Reference><Citation>Piniaeva A, Ignatyev G, Kozlovskaya L, Ivin Y, Kovpak A, Ivanov A, Shishova A, Antonova L, Khapchaev Y, Feldblium I, et al. Immunogenicity and safety of inactivated Sabin-Strain polio vaccine “PoliovacSin”: Clinical trials phase I and II. Vaccines (Basel). 2021;9(6):565. doi:10.3390/vaccines9060565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060565</ArticleId><ArticleId IdType="pmc">PMC8229617</ArticleId><ArticleId IdType="pubmed">34072466</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–94. doi:10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA) . Guideline for good clinical practice E6(R2). Step 5. [accessed
2021 June
30]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf.</Citation></Reference><Reference><Citation>World Health Organization &amp; WHO Expert Committee on Biological Standardization . WHO Expert Committee on Biological Standardization, sixty-fifth report. World Health Organ Tech Rep Ser. 2015;1–262. [Accessed 2022 February
28]. https://apps.who.int/iris/handle/10665/173739.</Citation><ArticleIdList><ArticleId IdType="pubmed">26714369</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawt L, Atkinson E, Tedcastle A, Pegg E, Minor P, Cooper G, Rigsby P, Martin J. 
Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). [accessed
2018. 
October 29 – November 2]. https://cdn.who.int/media/docs/default-source/biologicals/bs-documents-(ecbs)/2019-documents/bs.2018.2338_sipv_is_collaborative_study_report_version.pdf?sfvrsn=9b150f78_5&amp;download=true.</Citation></Reference><Reference><Citation>Jia S, Tang R, Li G, Hu Y, Liang Q. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. BMC Infect Dis. 2020;20(1):641. doi:10.1186/s12879-020-05348-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05348-1</ArticleId><ArticleId IdType="pmc">PMC7460787</ArticleId><ArticleId IdType="pubmed">32867698</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O’-Brien KL, Perera R, Pollard AJ. The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: An individual participant meta-analysis. JAMA Pediatr. 2017;171(7):637–46. doi:10.1001/jamapediatrics.2017.0638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.0638</ArticleId><ArticleId IdType="pmc">PMC5710349</ArticleId><ArticleId IdType="pubmed">28505244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora C, Thierry-Carstensen B, Tingskov PN, Sorensen C, Wachmann H, Bandyopadhyay AS, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2020;38(3):530–38. doi:10.1016/j.vaccine.2019.10.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.10.064</ArticleId><ArticleId IdType="pmc">PMC6983932</ArticleId><ArticleId IdType="pubmed">31703934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>